Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
RYTARY
Generic name / active ingredient
carbidopa and levodopa extended-release capsules
Dosage-form class
Carbidopa/levodopa fixed two-ingredient extended-release oral capsules: 23.75/95, 36.25/145, 48.75/195 and 61.25/245 mg; each paired strength states the two ingredients in one capsule and is not a milligram conversion table for SINEMET immediate-release tablets or another extended-release product
Route
Oral
Record reviewed
2026-08-29

Copy from the pack in hand

Source-linked reading points

  • The label says to swallow the capsule whole and not chew, divide or crush it or grind the pellets. For swallowing difficulty, the label allows carefully opening both halves, sprinkling the entire contents on 1–2 tablespoons of applesauce and consuming it immediately. Do not store it or take only part. Have a pharmacist or prescriber review a different actual product, food requirement or swallowing limitation.
  • RYTARY is not interchangeable with other carbidopa/levodopa products. SINEMET is an immediate-release tablet; STALEVO also contains entacapone; CREXONT, DHIVY, DUOPA and VYALEV have different forms or delivery systems. Do not self-combine, alternate by day, convert or substitute from total levodopa milligrams, paired numbers, appearance or an old prescription.
  • Do not suddenly stop or rapidly reduce RYTARY. The label describes hyperpyrexia, muscular rigidity, altered consciousness and autonomic instability after rapid reduction, withdrawal or changes in dopaminergic therapy. Use local emergency services immediately for high fever, marked rigidity, altered consciousness, breathing or circulatory instability, and take the pack and complete medicine list.
  • Sudden sleep during daily activities, marked somnolence or dizziness may impair driving or machinery use. Hallucinations, psychotic symptoms, intense urges involving gambling, spending, sex or eating, and new involuntary movements also require prompt contact with the care team. Family or carers may notice these changes first. The site does not adjust treatment from these symptoms.

Reviewed presentation examples — compare every field

  • Carbidopa 23.75 mg plus levodopa 95 mg per capsule; 100-capsule bottleNDC 64896-661-01
  • Carbidopa 23.75 mg plus levodopa 95 mg per capsule; 25-capsule bottleNDC 64896-661-09
  • Carbidopa 23.75 mg plus levodopa 95 mg per capsule; 240-capsule bottleNDC 64896-661-43
  • Carbidopa 23.75 mg plus levodopa 95 mg per capsule; 100-capsule bottleNDC 64896-661-99
  • Carbidopa 36.25 mg plus levodopa 145 mg per capsule; 100-capsule bottleNDC 64896-662-01
  • Carbidopa 36.25 mg plus levodopa 145 mg per capsule; 25-capsule bottleNDC 64896-662-09
  • Carbidopa 36.25 mg plus levodopa 145 mg per capsule; 240-capsule bottleNDC 64896-662-43
  • Carbidopa 36.25 mg plus levodopa 145 mg per capsule; 100-capsule bottleNDC 64896-662-99

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-29
Source record
6 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image